GreenRoc Accelerates their World Class Project to Production as Early as 2028. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHikma Pharmaceuticals Share News (HIK)

Share Price Information for Hikma Pharmaceuticals (HIK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,949.00
Bid: 1,952.00
Ask: 1,954.00
Change: -24.00 (-1.22%)
Spread: 2.00 (0.102%)
Open: 1,972.00
High: 1,982.00
Low: 1,949.00
Prev. Close: 1,973.00
HIK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Hikma signs Easyhaler deal with Orion

Mon, 13th Feb 2017 09:23

(ShareCast News) - Hikma Pharmaceuticals has signed an exclusive licensing and distribution agreement with Finland's Orion for its new Easyhaler combination product for the treatment of asthma and chronic obstructive pulmonary disease.Under the terms of the agreement, Hikma has the exclusive rights to register, distribute, market and sell the product in all of its MENA markets, leveraging the company's local presence, sales and marketing capabilities and regulatory expertise. Mazen Darwazah, vice chairman and chief executive officer of MENA and emerging markets said: "We are pleased to be adding this important product to our respiratory pipeline and we hope this collaboration with Orion will be the beginning of a long partnership for its Easyhaler device products in the MENA region. "Global partnerships are an integral part of our strategy to grow our portfolio in key therapeutic areas and improve patients' access to high-quality medicines."At 1020 GMT, the shares were up 0.9% to 1,955p.
More News
30 Apr 2021 07:57

LONDON MARKET PRE-OPEN: Barclays, AstraZeneca post sharp profit rises

LONDON MARKET PRE-OPEN: Barclays, AstraZeneca post sharp profit rises

Read more
30 Apr 2021 07:38

Hikma predicts generics revenue at top of guidance

(Sharecast News) - Hikma Pharmaceutical said it made a good start to 2021 and that annual revenue from generic treatments would be at the top of guidance.

Read more
23 Apr 2021 16:01

UK earnings, trading statements calendar - next 7 days

UK earnings, trading statements calendar - next 7 days

Read more
21 Apr 2021 12:08

LONDON MARKET MIDDAY: Stocks recover modestly; Netflix misses targets

LONDON MARKET MIDDAY: Stocks recover modestly; Netflix misses targets

Read more
21 Apr 2021 10:06

Hikma resumes asthma drug launch, Vectura pays special dividend

Hikma resumes asthma drug launch, Vectura pays special dividend

Read more
21 Apr 2021 09:01

LONDON MARKET OPEN: Stocks rise; Just Eat sinks on Germany competition

LONDON MARKET OPEN: Stocks rise; Just Eat sinks on Germany competition

Read more
21 Apr 2021 07:52

LONDON MARKET PRE-OPEN: Anto holds outlook, BHP cuts coal guidance

LONDON MARKET PRE-OPEN: Anto holds outlook, BHP cuts coal guidance

Read more
21 Apr 2021 07:30

Hikma resumes US launch of 'Advair Diskus' generic

(Sharecast News) - Hikma Pharmaceuticals has resumed the launch of its generic version of GlaxoSmithKline's 'Advair Diskus' in the United States, it announced on Wednesday, following Food and Drug Administration (FDA) approval of an amendment it submitted to its Abbreviated New Drug Application in January.

Read more
19 Apr 2021 16:02

UK dividends calendar - next 7 days

UK dividends calendar - next 7 days

Read more
16 Apr 2021 14:54

UK shareholder meetings calendar - next 7 days

UK shareholder meetings calendar - next 7 days

Read more
31 Mar 2021 17:04

LONDON MARKET CLOSE: Stocks end lower; investors shun Deliveroo

LONDON MARKET CLOSE: Stocks end lower; investors shun Deliveroo

Read more
31 Mar 2021 13:40

Wednesday broker round-up

(Sharecast News) - Hikma: Jefferies upgrades to buy with a target price of 2,870p.

Read more
31 Mar 2021 12:17

LONDON MARKET MIDDAY: Biden spends big; Deliveroo dives on debut

LONDON MARKET MIDDAY: Biden spends big; Deliveroo dives on debut

Read more
31 Mar 2021 11:56

Jefferies upgrades Hikma to 'buy'

(Sharecast News) - Analysts at Jefferies upgraded drugmaker Hikma Pharmaceuticals from 'hold' to 'buy' on Wednesday, stating the group's share price was yet to reflect "a series of upcoming product catalysts".

Read more
31 Mar 2021 09:37

BROKER RATINGS: BP cut by Morgan Stanley; Jefferies raises Hikma

BROKER RATINGS: BP cut by Morgan Stanley; Jefferies raises Hikma

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.